335 related articles for article (PubMed ID: 33002095)
21. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
Misenko SM; Patel DS; Her J; Bunting SF
Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483
[TBL] [Abstract][Full Text] [Related]
22. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
24. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes.
Klein G; Klein E; Kashuba E
Biochem Biophys Res Commun; 2010 May; 396(1):67-73. PubMed ID: 20494113
[TBL] [Abstract][Full Text] [Related]
25. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
26. A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.
Ho TH; Sitz J; Shen Q; Leblanc-Lacroix A; Campos EI; Borozan I; Marcon E; Greenblatt J; Fradet-Turcotte A; Jin DY; Frappier L
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743367
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district.
Huang YH; Wu QL; Zong YS; Feng YF; Liang JZ; Hou JH; Shao Q; Fu J
Ai Zheng; 2009 Aug; 28(8):805-12. PubMed ID: 19664325
[TBL] [Abstract][Full Text] [Related]
31. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
Hilmi K; Jangal M; Marques M; Zhao T; Saad A; Zhang C; Luo VM; Syme A; Rejon C; Yu Z; Krum A; Fabian MR; Richard S; Alaoui-Jamali M; Orthwein A; McCaffrey L; Witcher M
Sci Adv; 2017 May; 3(5):e1601898. PubMed ID: 28560323
[TBL] [Abstract][Full Text] [Related]
32. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
33. Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus.
Gutiérrez MI; Ibrahim MM; Dale JK; Greiner TC; Straus SE; Bhatia K
J Natl Cancer Inst; 2002 Dec; 94(23):1757-63. PubMed ID: 12464647
[TBL] [Abstract][Full Text] [Related]
34. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors.
Chen X; Kamranvar SA; Masucci MG
Oncogene; 2016 Jul; 35(29):3807-16. PubMed ID: 26592445
[TBL] [Abstract][Full Text] [Related]
36. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
38. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus nuclear antigen 3C interact with p73: Interplay between a viral oncoprotein and cellular tumor suppressor.
Sahu SK; Mohanty S; Kumar A; Kundu CN; Verma SC; Choudhuri T
Virology; 2014 Jan; 448():333-43. PubMed ID: 24314664
[TBL] [Abstract][Full Text] [Related]
40. Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.
Hill ER; Koganti S; Zhi J; Megyola C; Freeman AF; Palendira U; Tangye SG; Farrell PJ; Bhaduri-McIntosh S
J Virol; 2013 Nov; 87(21):11438-46. PubMed ID: 23966384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
